American Society of Gene & Cell Therapy

08/26/2026

Join leading minds in oncology for a two half-day virtual event exploring the latest advancements in cell and gene therapies for cancer.

Hear from pioneering researchers and innovators as they dive into some of the most compelling areas shaping CGTs for cancer today.

The presentations will cover:
• Precision gene engineering for programmable immune cell therapies
• The in vivo cell therapy frontier
• Novel approaches to CAR architecture
• Reprogramming the tumor microenvironment


Beyond the presentations, take the conversation further through interactive breakout sessions and live Q&As designed to encourage discussion, connection and deeper exploration of the field’s biggest opportunities and challenges.

Register today to be part of the conversation. https://bit.ly/4aX9OVW

08/26/2026

Join leading minds in oncology for a two half-day virtual event exploring the latest advancements in cell and gene therapies for cancer. 

Hear from pioneering researchers and innovators as they dive into some of the most compelling areas shaping CGTs for cancer today. Beyond the presentations, take the conversation further through interactive breakout sessions and live Q&As designed to encourage discussion, connection and deeper exploration of the field’s biggest opportunities and challenges.

08/26/2026

The FDA has approved Genglycos (pariglasgene brecaparvovec), an AAV gene therapy developed by Ultragenyx Pharmaceuticals, for treatment of Glycogen Storage Disease Type Ia (GSDIa) in patients 8 years of age and older with a documented history of hypoglycemia requiring intensive dietary management. This approval marks the first approved therapy of its kind for individuals born with GSDIa.

Read our full blog post about the approval here:

The unbiased source for reliable, scientific information, news, and breakthroughs in gene and cell therapy.

08/25/2026

There’s still time to share your research!

We've extended our abstract submission deadline to September 1.

Don’t miss the opportunity to contribute to the conversations shaping what’s next.

Register and submit your abstract here: https://bit.ly/4wHH10l

08/25/2026

📰 Our latest edition of The Patient Press newsletter is now available! This month, read updates about OMB, check out our two new Patient Education resources, catch up on our recent Congressional Briefing on CGT for Rare Disease, and more.

Read The Patient Press now ➡️ https://bit.ly/4il1BiC

08/25/2026

There’s still time to share your research! We’ve extended our abstract submission deadline to September 1. Don’t miss the opportunity to contribute to the conversations shaping what’s next.

Head to our story to register and submit your abstract.

08/24/2026

CMC plays a critical role in advancing safe and effective cell and gene therapies, with ex vivo and in vivo approaches presenting unique considerations. 

Explore the challenges across both modalities and gain a practical framework for navigating development in our upcoming regulatory webinar. 

Register today to strengthen your CMC strategy and set your programs up for success - link in our story.

08/20/2026

Did you know gene therapy delivery does not always involve a virus? 🤔

Non-viral vectors are an evolving area of cell and gene therapy research, with potential to expand how future treatments are delivered.

Learn more about this kind of vector delivery within ASGCT's new patient education unit: https://bit.ly/3Ub2Y9G

08/19/2026

📢 Speaker announcement! ASGCT is pleased to welcome Inma Hernandez, PhD, Centers for Medicare and Medicaid Services, to the Policy Summit this September. Dr. Hernandez will be our featured speaker for a fireside chat on fostering access to . Register today to hear her perspectives on the future direction of CGT coverage and access, emerging reimbursement and pricing approaches, and policy considerations that affect patient access to approved therapies.

Early bird registration rates end today, August 19! Join us in person or virtually.

08/19/2026

ASGCT Past President Paula Cannon, PhD recently joined Cell & Gene Therapy Insights to reflect on the evolution of gene therapy from a bold scientific idea to an increasingly established clinical reality.

From navigating financial and regulatory barriers to exploring ways to reduce development costs, Paula shares her perspective on what it will take to expand patient access. She also discusses the growing role of patient education and the need to thoughtfully evaluate the risks and benefits of emerging therapies.

As more therapies reach patients, what will it take to overcome the policy, access and development challenges that remain? Read the full interview to explore Paula’s perspective: https://bit.ly/4cMQb3y

“Five years from now, when we have treated and cured many people with sickle cell disease, it will begin to feel mundane.”Abi Pinchbeck, Editor, Cell and Gene Therapy Insights , speaks with Paula Cannon, Distinguished Professor of Molecular Microbiology and Immunology, Keck School of Medicine of...